The Ministry of Health of the Russian Federation has given permission to the Federal Biomedical Agency for clinical trials of the drug from COVID-19, volunteers are being recruited, the agency’s website says.
As specified, within this phase it is planned to study the safety and tolerability of the drug in healthy people. These tests will be carried out at the Institute of Immunology of the FMBA of Russia. Volunteers are currently being recruited.
Earlier, the head of the department Veronika Skvortsova said that this drug is etiotropic, affecting directly the virus. According to her, preclinical studies have shown the safety of the drug and its almost one hundred percent effectiveness.